연구성과로 돌아가기

2021 연구성과별 연구자 정보 (202 / 2991)

※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Document Title Author Full Name Author Short Name Index Corresponding Address ResearcherID ResearcherID Author Name ORCID ORCID Author Name Related Email
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma Bae, Inhwan Bae, I 9 Hanmi Pharmaceut Co Ltd, Dept New Chem Ent Discovery, Hanmi Res Ctr, Seoul, South Korea 0000-0001-5390-2401 Bae, InHwan twkimmd@amc.seoul.kr;shivam@gene.com;
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma Dela Cruz, Darlene Dela Cruz, D 10 Genentech Inc, Dept Translat Oncol, San Francisco, CA 94080 USA twkimmd@amc.seoul.kr;shivam@gene.com;
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma Hunsaker, Thomas Hunsaker, T 11 Genentech Inc, Dept Translat Oncol, San Francisco, CA 94080 USA twkimmd@amc.seoul.kr;shivam@gene.com;
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma Klijn, Christiaan Klijn, C 12 Genentech Inc, Dept Bioinformat, San Francisco, CA 94080 USA twkimmd@amc.seoul.kr;shivam@gene.com;
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma Liau, Nicholas P. D. Liau, NPD 13 Genentech Inc, Dept Struct Biol, San Francisco, CA 94080 USA HJI-9205-2023 Liau, Nicholas 0000-0002-3887-899X Liau, Nicholas twkimmd@amc.seoul.kr;shivam@gene.com;
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma Lin, Eva Lin, E 14 Genentech Inc, Dept Discovery Oncol, San Francisco, CA 94080 USA twkimmd@amc.seoul.kr;shivam@gene.com;
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma Martin, Scott E. Martin, SE 15 Genentech Inc, Dept Discovery Oncol, San Francisco, CA 94080 USA twkimmd@amc.seoul.kr;shivam@gene.com;
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma Modrusan, Zora Modrusan, Z 16 Genentech Inc, Dept Microchem Prote & Lipid, San Francisco, CA 94080 USA twkimmd@amc.seoul.kr;shivam@gene.com;
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma Piskol, Robert Piskol, R 17 Genentech Inc, Dept Bioinformat, San Francisco, CA 94080 USA twkimmd@amc.seoul.kr;shivam@gene.com;
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma Segal, Ehud Segal, E 18 Genentech Inc, Dept Translat Oncol, San Francisco, CA 94080 USA twkimmd@amc.seoul.kr;shivam@gene.com;
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma Venkatanarayan, Avinashnarayan Venkatanarayan, A 19 Genentech Inc, Dept Discovery Oncol, San Francisco, CA 94080 USA twkimmd@amc.seoul.kr;shivam@gene.com;
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma Ye, Xin Ye, X 20 Genentech Inc, Dept Discovery Oncol, San Francisco, CA 94080 USA twkimmd@amc.seoul.kr;shivam@gene.com;
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma Yin, Jianping Yin, JP 21 Genentech Inc, Dept Struct Biol, San Francisco, CA 94080 USA twkimmd@amc.seoul.kr;shivam@gene.com;
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma Zhang, Liangxuan Zhang, LX 22 Genentech Inc, Dept Oncol Biomarker Dev, San Francisco, CA 94080 USA twkimmd@amc.seoul.kr;shivam@gene.com;
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma Kim, Jin-Soo Kim, JS 23 Seoul Natl Univ, Dept Internal Med, Boramae Med Ctr, Seoul, South Korea AGF-2385-2022 Kim, In-Ryoung twkimmd@amc.seoul.kr;shivam@gene.com;
페이지 이동: